These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32507853)

  • 21. Stromal Clues in Endometrial Carcinoma: Loss of Expression of β-Catenin, Epithelial-Mesenchymal Transition Regulators, and Estrogen-Progesterone Receptor.
    Senol S; Sayar I; Ceyran AB; Ibiloglu I; Akalin I; Firat U; Kosemetin D; Engin Zerk P; Aydin A
    Int J Gynecol Pathol; 2016 May; 35(3):238-48. PubMed ID: 26367784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2-positive endometrial cancer subtype carries poor prognosis.
    Lapińska-Szumczyk S; Supernat A; Majewska H; Gulczyński J; Luczak A; Biernat W; Wydra D; Zaczek AJ
    Clin Transl Sci; 2014 Dec; 7(6):482-8. PubMed ID: 25201050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
    Kamat AA; Coffey D; Merritt WM; Nugent E; Urbauer D; Lin YG; Edwards C; Broaddus R; Coleman RL; Sood AK
    Cancer; 2009 Jun; 115(12):2684-92. PubMed ID: 19396818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
    Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications.
    Rambau P; Kelemen LE; Steed H; Quan ML; Ghatage P; Köbel M
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
    Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
    Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile.
    Alafraidi M; Hoang L; Howitt BE; Longacre TA; McAlpine JN; Jamieson A; Singh N; Gilks CB; Pors J
    Histopathology; 2024 Oct; 85(4):660-670. PubMed ID: 38890776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
    Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
    Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma.
    Mhawech-Fauceglia P; Wang D; Samrao D; Liu S; DuPont NC; Pejovic T
    Gynecol Oncol; 2013 Jul; 130(1):174-80. PubMed ID: 23578537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium.
    Kim KH; Choi JS; Kim JM; Choi YL; Shin YK; Lee HC; Seong IO; Kim BK; Chae SW; Kim SH
    Histol Histopathol; 2009 Mar; 24(3):309-16. PubMed ID: 19130400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-1 system and sex steroid receptor gene expression in human endometrial cancer.
    Singer CF; Kronsteiner N; Marton E; Walter I; Kubista M; Czerwenka K; Schreiber M; Tschugguel W; Wieser F; Kubista E
    Gynecol Oncol; 2002 Jun; 85(3):423-30. PubMed ID: 12051868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and prognostic value of WISP-1 in patients with endometrial endometrioid adenocarcinoma.
    Tang Q; Jiang X; Li H; Lin Z; Zhou X; Luo X; Liu L; Chen G
    J Obstet Gynaecol Res; 2011 Jun; 37(6):606-12. PubMed ID: 21564416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
    Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
    Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylation profiles of endometrioid and serous endometrial cancers.
    Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
    Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
    Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
    Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.
    Kapucuoglu N; Aktepe F; Kaya H; Bircan S; Karahan N; Ciriş M
    Pathol Res Pract; 2007; 203(3):153-62. PubMed ID: 17317031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
    Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.